Health
First in Human Study with Novel Antisense Oligonucleotide – Mirage News
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a…
A single intravenous dose of MRG-110, an anti-microRNA drug, significantly reduced miR-92a levels in the blood of healthy humans. Inhibition of miR-92a has shown beneficial effects in animal models, including improved vascularization after myocardial infarction, and accelerated wound healing, according to the peer-reviewed journal Nucleic Acid Therapeutics. Click here to read the article for free through September 12, 2020.
“Based on documented, promising therapeutic potential, locked nucleic a…
-
General21 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General23 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
General14 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test
-
Noosa News18 hours ago$20 million program to help women return to work